Developmental and physiological changes in children contribute to
variation in drug disposition with age. Additionally, critically ill children
suffer from various life-threatening conditions that can lead to
pathophysiological alterations that further affect pharmacokinetics (PK). Some
factors that can alter PK in this patient population include variability in
tissue distribution caused by protein binding changes and fluid shifts, altered
drug elimination due to organ dysfunction, and use of medical interventions that
can affect drug disposition (e.g., extracorporeal membrane oxygenation and
continuous renal replacement therapy). Performing clinical studies in critically
ill children is challenging because there is large inter-subject variability in
the severity and time course of organ dysfunction; some critical illnesses are
rare, which can affect subject enrollment; and critically ill children usually
have multiple organ failure, necessitating careful selection of a study design.
As a result, drug dosing in critically ill children is often based on
extrapolations from adults or non-critically ill children. Dedicated clinical
studies in critically ill children are urgently needed to identify optimal
dosing of drugs in this population. This review will summarize the
effect of critical illness on pediatric PK, the challenges associated with
performing studies in this vulnerable subpopulation, and the clinical PK studies
performed to date for commonly used drugs.